94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Allergy
Sec. Skin Allergy
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1564528
This article is part of the Research Topic Biomarkers in Allergic Eczema View all 5 articles
Scratching the Surface: Biomarkers and Neurobiomarkers for Improved Allergic Contact Dermatitis Management
Provisionally accepted- New York Medical College, Valhalla, United States
Allergic contact dermatitis (ACD), also known as allergic eczema, is a common inflammatory skin disorder that affects millions of Americans and imposes significant physical, psychological, and economic burdens. Differentiating ACD from other forms of dermatitis remains a challenge, with patch testing as the gold standard. Despite its utility, patch testing can lack diagnostic accuracy, highlighting the importance of molecular biomarkers to refine diagnosis and treatment. Advances in transcriptomics and machine-learning have enabled the identification of biomarkers involved in ACD, such as loricrin (LOR), ADAM8, CD47, BATF, SELE, and IL-37. Moreover, biomarkers such as LOR, NMF, and TEWL, may have prognostic value in evaluating therapeutic response. Emerging neurological biomarkers (neurobiomarkers), including IL-31 and TRPV1, target pathways involved in the pruritic and inflammatory responses, offering novel therapeutic targets as well. This mini review summarizes current ACD treatments, biomarkers for targeted therapies, and emphasizes the role of neurobiomarkers in ACD treatment. Additional research on the validity of the therapeutic potential of these biomarkers is necessary to improve ACD treatment and outcomes.
Keywords: neurobiomarkers, Pruritus, Inflammation, IL-31, Allergic contact dematitis
Received: 21 Jan 2025; Accepted: 24 Feb 2025.
Copyright: © 2025 Sasaki, Sargen, Maskey and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiu-Min Li, New York Medical College, Valhalla, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.